At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 25 enrolled
Drug / intervention
Thalidomide, cyclophosphamide and prednisonedrug
Likely dose
Thalidomide, cyclophosphamide and prednisone 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial
In Brief
A Phase 2 clinical trial evaluating Thalidomide, cyclophosphamide and prednisone for Multicentric Castleman Disease. Targeting 25 participants across 1 site.
Detailed Summary
To explore the effectiveness and safety of thalidomide, cyclophosphamide and prednisone (TCP regimen) in newly diagnosed Multicentric Castleman's disease (MCD) patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMulticentric Castleman Disease
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedFeb 2017
Primary CompletionJan 2020
Study CompletionJan 2021
TodayJul 2026
First PostedFeb 3, 2017
Enrollment StartJan 1, 2017
Primary CompletionJan 1, 2020
Study CompletionJan 1, 2021
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 9.4 years ago
Interventions
Thalidomide, cyclophosphamide and prednisonedrug
* Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year; * Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year; * Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year.